Physician profile
Juen Kim
NPI 1578862413
$7,542.46
in general payments reported to CMS, 2019-2025
22 companies · $2,994 in 2025
The $2,994 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $764 · 2023: $1,699 · 2024: $1,645 · 2025: $2,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,762 · Consulting Fee: $1,446 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,762.28 |
| Consulting Fee | $1,446.00 |
| Education | $129.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,494.07 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,190.32 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $1,044.80 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Optinose US, INC. | $571.46 | 2022-2025 | |
| Glaxosmithkline, LLC. | $540.01 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Alk-Abello, INC | $312.43 | 2022-2023 | Ragwitek, Grastek, Odactra |
| Csl Behring | $265.05 | 2024-2025 | Hizentra, Andembry, Haegarda |
| Abbvie INC. | $259.52 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $167.11 | 2023-2025 | |
| Dermavant Sciences, INC. | $148.51 | 2023-2024 | Vtama |
| Blueprint Medicines Corporation | $148.39 | 2023 | Ayvakit |
| Regeneron Pharmaceuticals, INC. | $110.46 | 2024 | Dupixent |
| Biocryst US Sales Co., LLC | $65.00 | 2022 | |
| Genentech USA, INC. | $43.49 | 2024 | Xolair |
| Electromed, INC. | $39.81 | 2024 | Smartvest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $38.65 | 2025 | Neffy |
| Kaleo, INC. | $22.08 | 2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $19.95 | 2025 | Cuvitru |
| Paratek Pharmaceuticals, INC. | $18.64 | 2025 | Xhance, Nuzyra |
| Amgen INC. | $18.18 | 2023 | Tezspire |
| Organon LLC | $14.53 | 2025 | |
| Bio Products Laboratory USA, INC. | $10.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juen Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.